内容摘要：She described the scale of destruction as unimaginable.

She described the scale of destruction as unimaginable.

from about 1,000 prepubertal boys.It’s impossible to tell if enough stem cells are in each tiny sample to matter. But in 2019, Orwig used preserved testicular tissue from a young male monkey that, in an animal version of IVF, led to the birth of a healthy baby monkey.

By 2023, Orwig was ready to reimplant now-grown cancer survivors’ cells when Hsu — not ready to start a family yet but curious about his long-ago study participation — reached out.“We’re not expecting a miracle result,” cautioned Orwig, whose colleagues transplanted Hsu’s thawed cells in November 2023.this week, Orwig reported the injection, guided by ultrasound to the right spot, was safe and easy to perform. His work has not yet been reviewed by other scientists.

And Orwig said it’s too soon to know if the experiment worked and standard tests likely won’t tell, as animal testing found assisted reproduction techniques were needed to detect and retrieve small amounts of sperm. Still, he hopes the ongoing research will alert more families to consider fertility preservation so they’d have the option if it eventually pans out.Belgian researchers announced a similar experiment in January, implanting pieces of testicular tissue rather than cells in a childhood cancer survivor.

“These developments are of great importance,” said researcher Ellen Goossens of Vrije Universiteit Brussel. While animal research “was very promising, transplantations in humans will be the only way” to tell if this really works.

Similar research with immature ovarian tissue is underway for female childhood cancer survivors, too, noted Dr. Mahmoud Salama, who directs the Oncofertility Consortium at Michigan State University.The findings are based on measuring antibodies in participants’ blood after 29 days, an indication of short-term disease protection.

Last week, Moderna pushed its target date for the vaccine’s approval to 2026 after the Food and Drug Administration requested a more direct measure: how much the shot lowered the risk of disease.“I agree in this case with FDA that efficacy data are important to see,” Poland said.

Health Secretary Robert F. Kennedy Jr. has cast doubt on the safety of mRNA vaccines, but Moderna President Stephen Hoge told investors in an earnings call last week that talks with the FDA were productive and “business as usual.”the FDA was asking the company to run a new clinical trial of its protein-based COVID-19 vaccine after the agency grants full approval, sowing uncertainty about other vaccine updates.